^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ankeda (bevacizumab biosimilar)

    i
    Other names: QL1101, QL-1101
    Associations

    News

    Trials
    Company:
    Qilu Pharma
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial
    |
    Avastin (bevacizumab) • Ankeda (bevacizumab biosimilar)
    10ms
    A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=25, Recruiting, Yongpeng Wang | Not yet recruiting --> Recruiting | Initiation date: Oct 2022 --> Jul 2023
    Enrollment open • Trial initiation date • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    AiRuiYi (fluzoparib) • Ankeda (bevacizumab biosimilar)
    over1year
    A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Yongpeng Wang
    New P2 trial • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    AiRuiYi (fluzoparib) • Ankeda (bevacizumab biosimilar)
    3years
    Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. (PubMed, Cancer Biol Med)
    QL1101 showed similar efficacy and safety profiles as compared to bevacizumab among Chinese patients with untreated locally advanced non-squamous NSCLC.
    Clinical • P3 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    carboplatin • paclitaxel • Ankeda (bevacizumab biosimilar)
    over3years
    BEVTOR: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    Clinical • New P2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    Loqtorzi (toripalimab-tpzi) • Ankeda (bevacizumab biosimilar)